Diagnosis and treatment in chronic hepatitis B: Recent advances;Epatite cronica da virus B. Recenti progressi nella diagnosi e nel trattamento

Recenti Progressi in Medicina

Volumn 93, Issue 7-8, 2002, Pages 397-402

  Bernardi, Mauro ^a   Biselli, Maurizio ^a   Gramenzi, Annagiulia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic hepatitis B; Diagnosis, therapy

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIVIRUS AGENT; GANCICLOVIR; INTERFERON; LAMIVUDINE; THYMOSIN ALPHA1; VIRUS DNA;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; VIRUS HEPATITIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; DRUG RESISTANCE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VIRUS REPLICATION; VITAMIN E;

EID: 17544402283     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Chronic hepatitis in HBsAg carrier with serum HBV-DNA and anti-HBe
2. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" value
3. HBV-DNA in the sera of HBsAg carriers: A marker of active hepatitis B virus replication in the liver
4. Quantitation assay for hepatitis B virus DNA, standardisation and quality control
5. Occult hepatitis B virus infection: A hidden menace?
6. "Occult" hepatitis B virus as source of infection in liver transplant recipients
7. Lamivudine therapy of WHV-infected woodchucks
8. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen
9. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B
10. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
11. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha
12. Long-term remission of chronic hepatitis B after alpha-interferon therapy
13. Efficacy of thymosin alpha 1 in patients with chronic hepatitis B: A randomized, controlled trial
14. Thymosin α1 treatment of chronic hepatitis B: A multicenter placebo-controlled double bind study
15. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody and hepatitis B virus DNA-positive chronic hepatitis B
16. Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial
17. Vitamin E for chronic hepatitis B
18. Vitamin E as treatment for chronic hepatitis B: Results of a randomized controlled pilot trial
19. Therapy with nucleoside analogues for hepatitis B virus infection
20. A preliminary trial of Lamivudine for chronic hepatitis B infection
21. Lamivudine therapy for chronic hepatitis B: A six months randomised dose ranging study
22. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
23. A one-year trial of lamivudine for chronic hepatitis B
24. Lamivudine as initial treatment for chronic hepatitis B in the United States
25. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
26. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
27. Seroconversion after lamivudine treatment is not durable in chronic hepatitis B
28. Hepatitis B virus reactivation after lamivudine discontinuation
29. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
30. Long-term follow-up of patients with anti-HBe/HBV-DNA positive chronic hepatitis B treated for 12 months with lamivudine
31. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
32. Long-term therapy of chronic hepatitis B with lamivudine
33. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
34. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
35. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation
36. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort
37. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
38. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation
39. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
40. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
41. Hepatitis B reactivation after lamivudine
42. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
43. Randomised trial in hepatitis e antigen negative patients with replicating virus with ganciclovir vs lamivudine in combination with IFN-α. Evaluation of long-term efficacy